revascularization

First results of bioabsorbable metal scaffolds DREAMS

Original title:&nbsp;Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial.&nbsp;Reference:&nbsp;Michael Haude et al. Lancet 2013; 381: 836&ndash;44. Bioabsorbable scaffolds could improve vasomotion, remodelling and facilitate new interventions, both percutaneous and surgical. This new bioabsorbable scaffold, different from the<a href="https://solaci.org/en/2013/04/18/first-results-of-bioabsorbable-metal-scaffolds-dreams/" title="Read more" >...</a>

5 Year Follow Up Outcome of Zotarolimus Eluting Stent

Original title:&nbsp;The &#8220;Final&#8221; 5-Year Follow-Up From the ENDEAVOR IV Trial Comparing a Zotarolimus-Eluting Stent With a Paclitaxel-Eluting Stent. ENDEAVOR IV Investigators&nbsp;Reference:&nbsp;Ajay J. Kirtane et al. J Am Coll Cardiol Intv 2013. Article in press. The ENDEAVOR IV was a randomized controlled study with a noninferiority design that compared the Endeavor zotarolimus eluting stent (Medtronic, Santa<a href="https://solaci.org/en/2013/04/12/5-year-follow-up-outcome-of-zotarolimus-eluting-stent/" title="Read more" >...</a>

IVUS improves outcomes in long lesions with DES

Original title:&nbsp;Randomized Comparison of Clinical Outcomes between Intravascular Ultrasound and Angiography-Guided Drug-Eluting Stent Implantation for Long Coronary Artery Stenosis.&nbsp;Reference:&nbsp;Jung-Sun Kim et al. J Am Coll Cardiol Intv 2013. Article in press. Treating long lesions is difficult and the chance of instant thrombosis may be higher in these lesions. Coronary intravascular ultrasound (IVUS) can help in<a href="https://solaci.org/en/2013/04/11/ivus-improves-outcomes-in-long-lesions-with-des/" title="Read more" >...</a>

In diabetic patients, Everolimus eluting stents could perform better than Paclitaxel eluting stents

Original title:&nbsp;Safety and Efficacy of Everolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in a Diabetic Population&nbsp;Reference:&nbsp;Ana Laynez et, al. Catheterization and Cardiovascular Intervention 81:759-765 (2013) Everolimus eluting stents have already been compared with paclitaxel eluting stents in the general population, and they have proved to perform best, especially as regards revascularization and in-stent thrombosis.&nbsp; However, these data<a href="https://solaci.org/en/2013/04/09/in-diabetic-patients-everolimus-eluting-stents-could-perform-better-than-paclitaxel-eluting-stents/" title="Read more" >...</a>

The largest series of femoropopliteal in-stent restenosis to date 

Original title:&nbsp;Treatment of Femoropopliteal In-Stent Restenosis With Paclitaxel-Eluting Stents. Zilver PTX Global Registry. ZILVER-PTX.&nbsp;Reference:&nbsp;Thomas Zeller et al. J Am Coll Cardiol Intv 2013;6:274&ndash;81. Femoropopliteal in-stent restenosis (ISR) is reported in between 19% and 37% of lesions a year and this incidence increases with lesion length.&nbsp; The ZILVER-PTX study tested the self-expanding paclitaxel-eluting nitinol stent (Cook<a href="https://solaci.org/en/2013/04/08/the-largest-series-of-femoropopliteal-in-stent-restenosis-to-date/" title="Read more" >...</a>

Paclitaxel eluting balloon in the femoropopliteal region

Original title:&nbsp;Paclitaxel-Coated Versus Uncoated Balloon Angioplasty Reduces Target Lesion Revascularization in Patients With Femoropopliteal Arterial Disease. A Meta-Analysis of Randomized Trials.&nbsp;Reference:&nbsp;Salvatore Cassese et al. Circ Cardiovasc Interv. 2012;5:582-589. Balloon angioplasty is one of the most frequent alternatives used in patients with peripheral vascular disease, especially in the femoropopliteal region.&nbsp; However, its effectiveness is reduced in<a href="https://solaci.org/en/2013/03/27/paclitaxel-eluting-balloon-in-the-femoropopliteal-region/" title="Read more" >...</a>

Critical limb ischemia, always try to revascularize

Original title:&nbsp;Endovascular Treatment for Infrainguinal Vessels in Patients With Critical Limb Ischemia : OLIVE Registry, a Prospective, Multicenter Study in Japan With 12-Month Follow-up.&nbsp;Reference:&nbsp;Osamu Iida et al. Circ Cardiovasc Interv. 2013;6:00-00 Patients with critical limb ischemia typically reveal rest pain and ischemic ulcers or gangrene. Prognosis is poor and mortality and amputation rate are elevated.<a href="https://solaci.org/en/2013/02/15/critical-limb-ischemia-always-try-to-revascularize/" title="Read more" >...</a>

Modest correlation between IVUS and FFR in intermediate lesions assessment

Original title:&nbsp;FIRST: Fractional Flow Reserve and Intravascular Ultrasound Relationship Study&nbsp;Reference:&nbsp;Ron Waksman et al. J Am Coll Cardiol 2013. Article in Press For patients with angiographically assessed intermediate lesions such as stenosis between 40% and 80%, criteria that favor revascularization remains under debate.&nbsp; Fractional Flow Reserve (FFR) is considered the gold standard to assess intermediate lesions,<a href="https://solaci.org/en/2013/01/24/modest-correlation-between-ivus-and-ffr-in-intermediate-lesions-assessment/" title="Read more" >...</a>

Periprocedural stroke, unrelated to the access site?

Original title:&nbsp;Influence of access site choice on incidence of neurologic complications after percutaneous coronary intervention.&nbsp;Reference:&nbsp;Karim Ratib et al. Am Heart J 2012;0:1-8 Article in press. Neurological complications post coronary angioplasty (PCA) are sporadic but they are associated with eight times increased mortality.&nbsp; A transradial approach has multiple advantages over femoral but could theoretically have a<a href="https://solaci.org/en/2013/01/14/periprocedural-stroke-unrelated-to-the-access-site/" title="Read more" >...</a>

Ticagrelor, even better than we thought

Original title:&nbsp;Reduction in First and Recurrent Cardiovascular Events with Ticagrelor Compared with Clopidogrel in the PLATO Study.&nbsp;Reference:&nbsp;Payal Kohli et al. CIRCULATION AHA.112.124248. In analyzing randomized and monitored study outcomes, we usually observe that after the occurrence of any primary outcome event patients are typically blocked for further analysis.&nbsp; This practice limits the information on subsequent<a href="https://solaci.org/en/2013/01/08/ticagrelor-even-better-than-we-thought/" title="Read more" >...</a>

Top